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Abstract
The norepinephrine transporter (NET) is a major target for the evaluation of the cardiac sympathetic nerve system in patients 
with heart failure and Parkinson’s disease. It is also used in the therapeutic applications against certain types of neuroendo-
crine tumors, as exemplified by the clinically used 123/131I-MIBG as theranostic single-photon emission computed tomography 
(SPECT) agent. With the development of more advanced positron emission tomography (PET) technology, more radiotracers 
targeting NET have been reported, with superior temporal and spatial resolutions, along with the possibility of functional and 
kinetic analysis. More recently, fluorine-18-labelled NET tracers have drawn increasing attentions from researchers, due to 
their longer radiological half-life relative to carbon-11 (110 min vs. 20 min), reduced dependence on on-site cyclotrons, and 
flexibility in the design of novel tracer structures. In the heart, certain NET tracers provide integral diagnostic information 
on sympathetic innervation and the nerve status. In the central nervous system, such radiotracers can reveal NET distribution 
and density in pathological conditions. Most radiotracers targeting cardiac NET-function for the cardiac application consistent 
of derivatives of either norepinephrine or MIBG with its benzylguanidine core structure, e.g. 11C-HED and 18F-LMI1195. 
In contrast, all NET tracers used in central nervous system applications are derived from clinically used antidepressants. 
Lastly, possible applications of NET as selective tracers over organic cation transporters (OCTs) in the kidneys and other 
organs controlled by sympathetic nervous system will also be discussed.
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Abbreviations
1TC  One-tissue compartment
5-HTT  5-Hydroxytryptamine transporter, also 
SERT
AD  Alzheimer’s disease
ADHD  Attention-deficit hyperactivity disorder
ADMIRE-HF  ADreview Myocardial Imaging for Risk 




ASV  Adaptive servo-ventilation
BAT  Brown adipose tissue
BBB  Blood–brain barrier
BPND  Nondisplaceable binding potential
C6-hNET  Rat C6 glioma cells stably transfected 
with the human NET
CHF  Congestive heart failure
CNS  Central nervous system
COMT  Catechol-O-methyl transferase
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DMI  Desipramine










HF  Heart failure
HFpEF  Heart failure with preserved left ven-
tricular ejection fraction
HIBG  4-Hydroxy-3-iodobenzylguanidine




LV  Left ventricular
MA1  Multilinear analysis 1




MBF  Myocardial blood flow






NET  Norepinephrine transporter
NHP  Nonhuman primate
NS12137  Exo-3-[(6-fluoro-2-pyridyl)
oxy]-8-azabicyclo[3.2.1]-octane
OCTs  Organic cation transporters
PCC  Pheochromocytoma
PD  Parkinson’s disease





RI  Retention index
ROIs  Regions of interest
SERT  Serotonin transporter, also 5-HTT
SNS  Sympathetic nervous system
SPECT  Single-photon emission computed 
tomography
SUVmax  Maximum standardized uptake value
VAMT2  Vesicular monoamine transporter 2
VT  Volume of distribution
WAT  White adipose tissue
Introduction
The norepinephrine transporter (NET) serves as the main 
mechanism for terminating noradrenergic signaling at the 
synaptic gap and is essential for the reuptake of the neuro-
transmitter norepinephrine (NE), as well as the extraction 
of radiotracers targeting NET both in the central nervous 
system (CNS) and peripheral sympathetic nervous system 
(SNS). First, it is one of the main targets for pharmacologi-
cal intervention of related diseases, especially in the CNS. 
Drugs targeting NET are therapeutically used in the treat-
ment of disorders including depression, attention-deficit 
hyperactivity disorder (ADHD), and feeding disturbances 
(Bönisch and Brüss 2006). Second, in common cardiac dis-
eases, such as congestive heart failure (CHF) and ischemia, 
the cardiac SNS appears to be malfunctioning (Schroeder 
and Jordan 2012). Sympathetic innervation and function, as 
represented by the uptake kinetics of NET tracers, is used 
as a parameter for the diagnosis of heart diseases. Third, in 
Parkinson’s disease (PD), there is growing evidence that, 
besides depletion of dopamine, additional loss of noradren-
ergic neurons could also be involved in the clinical expres-
sion of motor symptoms (Delaville et al. 2011). Thus, NET 
is used as a marker to reveal the neurodegeneration and to 
diagnose parkinsonism. Lastly, due to the specific overex-
pression/up-regulation of NET in certain neuroendocrine 
tumors, radiolabeled compounds could also be used for 
chemotherapy, as seen with the use of currently the only 
clinically utilized NET ligand, 123/131I-meta-iodobenzyl-
guanidine (123/131I-MIBG), against neuroendocrine tumors. 
Physiologically, the extracted NEs are stably stored in the 
storage vesicles within the presynaptic neurons, shielding 
them from metabolism by monoamine oxidase (MAO). This 
mechanism is crucial for the diagnostic applications, as it 
reflects the systemic distribution and/or regional expression 
of NET in pathophysiological conditions. The current review 
focuses on the introduction of recent developments in NET-
targeting radiotracers for both cardiac and CNS diagnostic 
applications using either single-photon emission computed 
tomography (SPECT) or positron emission tomography 
(PET) technology. All the chemical structures of the radi-
otracers listed in this review are illustrated in Fig. 1, with 
a particular emphasis on advantageous fluorine-18-labeled 
ones. Radiotracers targeting cardiac NET are mainly devel-
oped from benzylguanidine or metaraminol, which are meta-
bolically stable against MAO, while radiotracers for CNS 
imaging are derivatives of known NET-selective antidepres-
sants. The discussion will not only examine their potential 
applications in HF, tumor diagnosis, and CNS disorders, but 
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also, more importantly, analyze new tracer design from a 
chemical and structural perspective, addressing the specifici-
ties of different transporters along with the pros and cons of 
the radiolabeling procedure. NET is the reuptake transporter 
of neurotransmitters or radiotracers into the neuronal termi-
nals. Therefore, the term “uptake-1” is used in publications 
(including the present one) to represent NET-mediated tracer 
uptake. Traditionally, any extra-neuronal uptake would be 
labeled “uptake-2”, the molecular mechanism of which is 
not clearly identified, but will be explored in details in the 
discussion section.
SPECT tracers targeting NET
123I‑MIBG
As the only NET-targeting radiotracer currently used clini-
cally, 123I-MIBG, using SPECT technology, has demon-
strated favorable results in the diagnosis of cardiac diseases 
and has confirmed the utility of independent risk stratifi-
cation in adrenergic imaging. These conclusions derive 
from the accumulation of several years of clinical trials 
data in the landmark “ADreview Myocardial Imaging for 
Risk Evaluation in Heart Failure” (ADMIRE-HF) study, 
as well as the follow-up ADMIRE-HF extra study (Travin 
2017). Moreover, 123I-MIBG is used as a risk stratification 
tool for potential implantation of cardioverter defibrillators 
(ICD) in HF patients. The currently recruiting event-driven 
ADMIRE-ICD trial will provide further insight into its effi-
cacy in patient management and determine which patients 
benefits the most from the implantation (Travin 2017). In 
addition, a number of malignancies of endocrine origin 
also feature high NET expression, along with monoamines 
uptake and storage, which forms the foundation for using 
131I-MIBG as a therapeutic agent against neuroblastoma and 
various neuroendocrine tumors (Inaki et al. 2017; Agrawal 
et al. 2018). Pandit-Taskar and Modak (2017) have pre-
sented an overview of NET as a target for theranostics, with 
a particular focus on the current role and broader applica-
tion of MIBG and its analogues in neuroendocrine tumors. 
Very recently, based on the clinical study MIP-IB12B 
(NCT00874614), the Food and Drug Administration of the 
US has approved 131I-MIBG (AZEDRA, Progenics Phar-
maceuticals, Inc.) for the anticancer therapy of adult and 
pediatric patients (12 years and older) with pheochromocy-




























































































































Fig. 1  Currently reported radiotracers targeting NET. a Norepineph-
rine and NET tracers for cardiac imaging. From a structural point 
of view, the blue moiety represents the common core structure nor-
fenefrine, dark green represents benzylguanidine core structure, and 
purple represents phenethylguanidine moiety. Red symbolizes radi-
oactive isotopes (Chen et  al. 2015, 2019). b The CNS NET tracers 
derived from antidepressants. This figure was created using Chem-
Draw 16 for Mac
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Now, it is on an expanded study to evaluate the safety and 
tolerability (NCT02961941). In addition, due to the inter-
action between the sympathetic components of the various 
organs controlled by autonomic nervous system (e.g. kid-
ney, brain, and periphery), the application of 123I-MIBG and 
analogous NET radiotracers can also be broadened to assess 
the pathophysiological conditions in extra-cardiac organs, 
such as renal denervation and PD (Travin 2019). In the last 
couple of years, MIBG scintigraphy has been considered 
for use in the diagnosis of early stage parkinsonian disor-
ders. A study involving 600 patients has demonstrated that 
123I-MIBG has the diagnostic ability to distinguish PD from 
atypical parkinsonism. Almost half of the patients displayed 
positive correlation between decreased tracer uptake and 
PD. These findings demonstrated its sufficient diagnostic 
accuracy for detecting the early phase of PD (Kawazoe et al. 
2019). When diagnosing PD, use of 123I-ioflupane SPECT 
with 123I-MIBG cardiac scintigraphy association, has made 
it possible to achieve the most appropriate diagnosis in over 
90% cases (Niimi et al. 2017; Nuvoli et al. 2018; Okada et al. 
2018). In addition, 123I-MIBG is also helpful for differentiat-
ing Alzheimer’s disease (AD) from Lewy Body dementias 
(Nuvoli et al. 2018). Most recently, a study involving 115 
patients indicated a potential role for immediate (5 min) or 
early (15 min) acquisition (replacing that of 240 min) in PD 
patients, which paves the way to a faster validation (Frantel-
lizzi et al. 2020).
123I-MIBG is the first in the benzylguanidine series of 
NET tracers with guanidine moieties. It features a chemi-
cally polar structure, which ensures its long-term storage 
in granular vesicles after extraction. Its biological stability 
against MAO has set up a paradigm for subsequent tracer 
design. Despite being introduced 30 years ago, its disad-
vantages as a SPECT radiotracer limit further application. 
Among these disadvantages are poorer spatial resolution 
compared to PET, limited sensitivity in small lesions/small 
sized tumors, the necessity of several scanning protocols, 
as well as a delay between the tracer administration and 
result obtainment (Pfluger and Piccardo 2017). Therefore, 
in the last two decades, PET, rather than SPECT tracers has 
become the focus of research.
PET tracers targeting NET
11C‑HED
11C-Hydroxyephedrine (HED), as one of the first PET trac-
ers targeting NET, has been investigated intensively in Japan 
and the US, with studies involving a variety of patients 
confirming its feasibility in quantifying not only regional 
sympathetic denervation, but also other conditions as well 
(Fujita et al. 2016; Hiroshima et al. 2017; Aikawa et al. 
2017; Wang et al. 2018). Studies by Fujita et al. on 11C-HED 
PET involving 60 patients with left ventricular (LV) dys-
function as a predictor of all-cause death. Thirteen deceased 
patients were associated with significantly lower HED reten-
tion than those who survived (7.1 vs. 9.0, p = 0.015). This 
result demonstrated that cardiac sympathetic dysfunction as 
measured by 11C-HED PET (0.762 as retention per unit (/
min) as a hazard ratio) is related to poor survival rate in 
patients with LV dysfunction, independent of age (Fujita 
et al. 2016). This is in accordance with prior systematic 
investigation performed by only two other research groups 
(Pietilä et al. 2001; Fallavollita et al. 2014). Furthermore, 
by enrolling ten controls and thirteen patients, it was pos-
sible to correlate the 11C-HED PET with myocardial blood 
flow. The correlation coefficient demonstrated a significantly 
high relationship for both the whole left ventricle and three 
coronary territories, illustrating the potential of 11C-HED 
for simultaneous assessment of perfusion and neuronal func-
tion within a single scan, for the determination of mismatch 
(Hiroshima et al. 2017). In addition to global assessment, 
11C-HED has also been used for investigating regional sym-
pathetic denervation in HF patients with preserved left ven-
tricular ejection fraction (HFpEF). The results obtained from 
34 patients, along with 11 age-matched volunteers without 
HF, showed the global 11C-HED retention index to be sig-
nificantly lower and more heterogeneous in HFpEF patients 
than in volunteers (p < 0.01). Regional sympathetic dener-
vation is associated with both contractile dysfunction and 
the extent of myocardial scarring in patients with HFpEF 
(p ≤ 0.001). It is suggested that regional sympathetic den-
ervation may provide an integrated measure of myocardial 
damage in HFpEF patients (Aikawa et al. 2017). One of 
the advantages of cardiac imaging using PET tracers is the 
possibility of performing quantification analysis. There-
fore, in an effort to improve and expand the use of kinetic 
modeling, Wang et al., estimated the myocardiac tissue vol-
ume of distribution (VT) using both Logan and multilinear 
analysis 1 (MA1) graphical methods, while comparing with 
the one-tissue-compartment (1TC) standard model values. 
Both the MA1 and Logan models exhibited good agreement 
with 1TC, with similar regional patterns and global median 
values, as well as good-to-excellent test–retest repeatability 
(Wang et al. 2018). The Logan model underestimated VT due 
to the recognized noise bias. Logan and MA1 both exhibited 
similar test–retest variability, suggesting that they may be 
used in addition to 1TC in the modeling of 11C-HED kinet-
ics, with benefits of greater computational simplicity and 
the ability to mathematically visualize kinetic parameters for 
better quality assurance (Wang et al. 2018). Wu et al., inves-
tigated the reproducibility and repeatability of 11C-HED 
quantification of global cardiac innervation, regional den-
ervation and myocardial blood flow (MBF) in 20 patients. 
Their results demonstrated a more reliable repeatability with 
the simple retention index (RI) method as opposed to that of 
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the complex VT in quantitative measurement of both global 
and regional innervation, supporting the use of RI over VT 
for clinical trials in prediction of cause-specific mortality 
from sudden cardiac arrest (Wu et al. 2019). Most recently, 
11C-HED has also been used for the evaluation of adap-
tive servo-ventilation (ASV) in improving cardiac function 
of HF patients while comparing to 123I-MIBG. Increased 
heart/mediastinum ratio of 123I-MIBG imaging along with 
increased global 11C-HED RI confirmed the feasibility of 
ASV by demonstrating improved sympathetic nerve function 
(Tokuda et al. 2019). In addition to its clinical application, 
researchers continue to use 11C-HED as a preclinical tool for 
basic research studies, including in a rat model with transient 
myocardial ischemia. A large defect of 11C-HED due to the 
denervation in ischemic areas has confirmed the increased 
susceptibility of sympathetic neurons over cardiomyocytes 
during ischemic injury. It has been shown that the 11C-HED 
uptake defect areas in both the subacute and chronic phases 
after transient ischemia were clearly larger than the perfu-
sion defect areas in the midventricular wall. Partial rein-
nervation could be observed as the uptake of 11C-HED 
recovered in the subepicardial portion in the chronic phase 
(Werner et al. 2016). Furthermore, the potential cold mass 
effect of 11C-HED (specific activities 0.2–141.9 GBq/µmol) 
in healthy Wistar rats (ranging 0.2–60.4 µg/kg cold mass) 
was also investigated, in which a dose-dependent reduction 
of cardiac 11C-HED uptake with different specific activities 
was observed. With the cold mass dose increased from 0.2, 
1, 10 to 34 µg/kg, a subsequent decrease of tracer uptake in 
the left ventricular myocardium could be clearly recorded. 
Time–activity curves demonstrated that at the highest cold 
dose (34 µg/kg), the washout increased considerably, while 
both the low-dose curves (0.2 and 1 µg/kg) remained rela-
tively stable (Werner et al. 2018). In addition, in a longitu-
dinal setting, the cardiac uptake of 11C-HED in rat hearts 
reduced from M5, M11 to M15, while 18F-Fludeoxyglucose 
(18F-FDG) uptake remained stable during the same time 
period, indicating preserved myocardial viability. As has 
been previously reported, when compared to 123I-MIBG, the 
cardiac uptake of 11C-HED is at equilibrium and relies on 
the continuous leaking–reuptaking pathway by NET (Wer-
ner et al. 2015). Accordingly, an age-related deterioration of 
NET functionality might explain these findings, which are 
in accordance with results reported in human studies using 
other NET tracers (Tsuchimochi et al. 1995; Li et al. 2003).
As a radiotracer targeting NET, the applications of 11C-
HED are not only limited to the cardiac conditions such as 
HF. Wong et al. (2017) investigated the regional patterns 
of cardiac sympathetic denervation in PD using 11C-HED 
PET and determined the denervation rate of 39 patients. 
Their findings revealed the heterogeneity of cardiac sym-
pathetic denervation in PD. Over a 2-year interval, pro-
gressive decline occurred at a modest rate (as observed by 
11C-HED PET scans), with a regional preferential pattern, 
consistent with 18F-6-fluorodopamine results. In addition, 
similar to the application of 123I-MIBG in the diagnosis 
of neuroendocrine tumors, 11C-HED could be used as 
an accurate tool for the diagnosis/ruling out of PCC and 
PGL in complex clinical scenarios, in contrast to CT/MRI 
characterization. In a 2019 study by Vyakaranam et al. 
(2019), 11C-HED PET/CT was performed for a cohort of 
102 patients, where 19 patients were correctly identified 
as having PCC, 6 with PGL, and 75 successfully excluded 
from having either. Moreover, using 11C-HED PET as an 
indicator of sympathetic innervation (expressed as RI%), 
it is possible to predict levels of supraclavicular brown 
adipose tissue (BAT) in lean normal adult subjects. Fur-
thermore, it has been seen that cold-induced decrease in 
white adipose tissue (WAT) energy expenditure is less pro-
nounced in subjects with high amounts of activated BAT 
(Muzik et al. 2017).
From structural point of view, 11C-HED is derived from 
the earlier reported metaraminol, which is biologically stable 
against MAO due to its ephedrine structure, where the α- 
and N-methyl groups are able to prevent/slow down the pos-
sible enzymatic oxidation/deamination. 11C-HED contains 
two chiral centers. Although both stereoisomers have dem-
onstrated high initial accumulation in murine model hearts, 
the (+)-isomer features a much faster efflux compared to the 
(−)-isomer, with effluxes of T1/2 2–3 h vs. 2–3 days, respec-
tively (Van Dort et al. 2000). Therefore, in potential kinetic 
studies, the (−)-stereoisomer is always used. In addition, 
due to its specific ephedrine structure, which is dissimilar 
from the other radiotracers possessing a guanidine moiety, 
its in vivo storage and release kinetics differ, as has been 
mentioned above (Werner et al. 2015).
Advantages of fluorine‑18 over carbon‑11‑labeled PET 
radiotracers
Over the last two decades, increasing attention has been 
placed on fluorine-18-labelled PET tracers (whose radioac-
tive half-life is 110 min) due to the following advantages 
over carbon-11-labelled tracers (whose half-life is 20 min): 
(1) it is more cost effective, given the possibility for its 
distribution from a central cyclotron facility, reducing the 
requirement of a costly on-site cyclotron; (2) there exists the 
potential of delayed and prolonged scans due to its longer 
half-life; (3) spatial resolution in PET imaging is improved 
as a consequence of its shorter travel distance prior to anni-
hilation, a result of the low positron energy of fluorine-18; 
(4) it allows for further alternatives and flexibility in novel 
tracer design, along with the possibility of improving the 
tracer stability against metabolism at sensitive positions 
(Kobayashi et al. 2017). As a result, the designing of new 
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NET tracers will focus on the use of fluorine-18 for subse-
quent development as to take the full advantages of PET 
imaging technology (Fig. 1a).
18F‑6F‑dopamine
18F-6F-dopamine is the metabolite of 18F-6F-DOPA and 
can be transported by NET into cardiac sympathetic nerves. 
The dosimetry of 18F-6F-dopamine for clinical PET scan 
has been estimated based on the results from rats and dogs 
(Goldstein et al. 1991). In initial human study, 18F-6F-do-
pamine is fast extracted by the sympathetic nerves, where it 
is translocated into vesicles (Deep et al. 1997). It can pro-
vide the neuronal uptake and the turnover of vesicles in the 
human heart (Goldstein et al. 1993). However, due to its pri-
mary amine structure, it undergoes fast metabolism in vivo 
with only 1–2% as parent tracer after 10 min injection (Ding 
et al. 1993). To visualize the cardiac sympathetic neurons, 
high dose will be needed due to the large excretion from 
urinary collecting system (Goldstein et al. 1994). After the 
administration of 18F-6F-dopamine, the concentration of the 
tracer in the heart declined bi-exponentially from the peak 
value. Tyramine chase (injection after radiotracer adminis-
tration) could increase the speed of tracer washout (Gold-
stein et al. 1997). Using 18F-6F-dopamine PET, it is possible 
to prove the decreased SNS function in hypertrophic cardio-
myopathy patients (Li et al. 2000). Goldstein and coworkers 
have further developed a kinetic model for 18F-6F-dopamine, 
which can successfully predict the tracer kinetics in vivo 
under certain pharmacological manipulations (Goldstein 
et al. 2002).
Similar to MIBG, due to its ability to be taken up by NET, 
18F-6F-dopamine is also used for diagnostic localization of 
PCC with high sensitivity (Pacak et al. 2001), with superior 
outcome compared to 123I-MIBG (Ilias et al. 2003; Mamede 
et al. 2006; Kaji et al. 2007). In several patient studies, 
18F-6F-dopamine showed equal sensitivity to localize non-
metastatic PCC when compared to 123I-MIBG, but much 
better for metastatic ones (Ilias et al. 2008; Timmers et al. 
2009a, b). It is helpful to distinguish between physiological 
adrenal gland uptake and pathological PCC uptake (Tim-
mers et al. 2007). In patient study with mostly adrenal PGL, 
18F-6F-dopamine is recommended over 18F-FDG, 123I-MIBG 
and 18F-DOPA (Timmers et al. 2009a, b), whereas when 
detecting head and neck PGL, 18F-DOPA proved to be the 
most effective one (King et al. 2011). Other application of 
18F-6F-dopamine include imaging proof of denervation in 
the painful feet of patients with diabetic neuropathy (Tack 
et al. 2002), detection of medullary thyroid cancer (Gour-
giotis et al. 2003), ageing-related cardiac SNS changes (Li 
et al. 2003), cardiac and extra-cardiac sympathetic denerva-
tion in PD with orthostatic hypotension patients (Tipre and 
Goldstein 2005), hypo-innervation in familial dysautonomia 
(Goldstein et al. 2008), prediction of PD in at-risk individu-
als (Goldstein et al. 2018). 18F-6F-dopamine was initially 
radiolabeled using electrophilic labeling method 18F-F2 with 
only 2.6% radiochemical yield and 13.2 GBq/µmol specific 
acitivity (Eskola et al. 2012). After changing to a nickel-
mediated radiofluorination method, the yield was improved 
to 12% (Zlatopolskiey et al. 2015). Most recently, the use of 
iodonium salt as precursor in a one-pot two-step automatic 
synthesis could increase the yield to 26% (Vāvere et al. 
2018) that allows the clinical trial of pediatric neuroblas-
toma imaging (IND 138638).
18F‑MFBG/PFBG
To investigate the fluorine-18 derivatives of MIBG, two 
methods have been used to introduce the fluorine directly 
onto the benzylguanidine core structure: (1) replacing the 
iodine with fluorine directly to obtain 18F-meta- and para-
fluorobenzylguanidine (18F-MFBG/PFBG, Garg et al. 1994); 
(2) adding an additional fluorine to the MIBG structure to 
get 18F-(4-fluoro-3-iodobenzyl)guanidine (18F-FIBG, Vaidy-
anathan et al. 1994, 1995). 18F-MFBG and PFBG were origi-
nally radiolabeled using a 3-step synthetic scheme. Selective 
uptake of both 18F-MFBG/PFBG isomers has been observed 
in mice at similar levels: slightly higher levels of adrenal 
uptake than in the heart, while the radiochemical yield of 
PFBG is relatively higher than MFBG (Garg et al. 1994). 
The specific uptake of 18F-MFBG and PFBG were similar 
when examined in rat C6 glioma cells stably transfected with 
the human NET (C6-hNET), but fourfold less than MIBG. 
PET imaging of 18F-MFBG has demonstrated comparable 
tumor accumulation to the SPECT tracer 123I-MIBG, but 
MFBG showed a significantly more rapid clearance (Zhang 
et al. 2014a). A follow-up study using five neuroblastoma 
cell lines and two xenografts expressing different levels of 
NET confirmed the lower affinity for NET and lower cel-
lular uptake of MFBG than MIBG, but the in vivo imaging 
and tissue radioactivity concentration measurements still 
demonstrated higher MFBG xenograft uptake and tumor-
to-normal organ ratios (Zhang et al. 2014b). Due to the 
development of iodonium salt as a precursor for the electron-
rich benzene ring radiofluorination method, the radiolabe-
ling of 18F-MFBG has been optimized to make the last step 
radiofluorination, followed by the total deprotection of Boc 
groups from guanidine moiety with an overall radiolabe-
ling time less than 1 hour. The average yield was greatly 
improved from 10–15% to 31% with > 99% radiochemical 
purity, which permits the automated production of multi-
dose batches of clinical grade MFBG (Hu et al. 2015). Based 
on these thorough preclinical evaluations, the first-in-human 
study was performed in ten patients, which showed excellent 
in vivo stability and safety as well as a favorable biodistribu-
tion with good targeting of lesions that makes it feasible for 
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same-day imaging of neuroendocrine tumors. The maximum 
standardized uptake value  (SUVmax) of lesions was 8.6 ± 9.6 
at 1–2 h and 9.2 ± 11.4 at 3–4 h after injection. It showed a 
two phases clearance from the blood pool and was primar-
ily excreted from the kidneys. Due to this, the bladder was 
exposed to the highest and longest amount of radiation expo-
sure faster than 123I-MIBG, counting 61–95% vs 11–26%, 
respectively, by 3 h after injection. 18F-MFBG demonstrated 
high promise for imaging in patients, especially for children 
with neuroblastoma (Pandit-Taskar et al. 2018).
18F‑FIBG and analogues
Analogously, Vaidyanathan et al., devised another method 
for the introduction of the extra fluorine-18 to MIBG, as 
opposed to replacing iodine, to form 18F-FIBG. Similar 
to the other fluorobenzylguanidine tracers, the original 
radiolabeling procedure consisted of multiple steps with 
a long synthesis time (130 min) and low radiochemical 
yield (5% decay corrected) due to the requirement of the 
electron-withdrawing group cyanide for the successful 
electrophilic radiofluorination. However, both in vitro 
binding studies on SK-N-SH human neuroblastoma cells 
and in vivo tissue distribution studies indicate comparable 
properties to MIBG (Vaidyanathan et al. 1994). Further 
in vitro assays of tracer binding were carried out to con-
firm the NET-specific and energy-dependent uptake mech-
anisms similar to those of MIBG. A blocking study using 
desipramine (DMI) in mice has further confirmed the NET 
specificity by reducing cardiac and adrenal uptake to 57% 
and 60%, respectively. Radiation dosimetry calculations 
also suggested that, as an important advantage, higher 
doses of 18F-FIBG could be administered to patients than 
124I-MIBG (Vaidyanathan et al. 1995). Presumably due to 
the encouraging results obtained from 18F-FIBG, the same 
research group also reversely examined 131I-FIBG and the 
corresponding alpha-emitter analogue 211At-(3-astato-
4-fluorobenzyl)guanidine (211At-AFBG), both of which 
were synthesized from the same precursor using similar 
radiolabeling methods with 50–60% and 65–70% yield, 
respectively (Vaidyanathan et al. 1996). Naturally, both 
131I-FIBG and 211At-AFBG demonstrated characteristics 
comparable to those of their parent compound MIBG 
in terms of NET-specific uptake in both cell-based and 
mouse studies. It is noteworthy that both new analogues 
show higher stability against dehalogenation in mice when 
compared to 131I-MIBG or 211At-MABG. They particu-
larly feature lower thyroidal uptake, presumably due to the 
introduction of fluorine—the strong electron-withdrawing 
effect of which stabilizes the C–I and C–At bond (Vaidy-
anathan et al. 1997a, b). Further cell studies suggested 
that when 125I-MIBG and 125I-FIBG metabolism occurs, 
it leads to the same metabolites, but not as the original 
halobenzylguanidine (Vaidyanathan et al. 2004). As pre-
viously reported, one of the main metabolites of MIBG 
is 4-hydroxy-3-iodobenzylguanidine (HIBG) (Mangner 
et al. 1986). As a consequence, the 4-fluoro substituent of 
FIBG greatly slows down the metabolism (i.e. defluorina-
tion and oxidation) when compared to MIBG. In a SK-
N-SH cell study, 70% of radioiodine activity remained 
from 125I-FIBG after 3 days of experiment, compared to 
just 30% for 125I-MIBG. This offers a positive hint toward 
future tracer design: the introduction of a fluorine may pro-
vide not only the possibility of deriving the known tracer 
into an 18F-labeled PET tracer without major changes in 
characteristics, but may also introduce further benefits, 
such as improving the tracer stability in vivo by prevent-
ing the enzymatic degradation. Presumably due to their 
difficult radiolabeling procedure and low radiochemical 
yield, these tracers have not drawn much attention from 
researchers. Most recently, however, again benefiting 
from the development of iodonium salt as the precursor 
for electron-rich aromatic radiofluorination, Yamaguchi 
et al., optimized the radiolabeling of both 18F-FIBG and 
131I-MIBG using a copper-mediated 2-step procedure 
with a mesityl(aryl)iodonium salt precursor. Their results 
reconfirm the feasibility of these compounds as diagnostic 
and therapeutic agents with high and specific accumulation 
in the PC12 xenograft tumor cells, along with high tumor-
to-background ratios in mice studies. 131I-FIBG displayed 
a higher and more prolonged retention in tumors when 
compared to 125I-MIBG, which resulted in greater dose-
dependent delay in tumor growth than with 131I-MIBG 
(Yamaguchi et al. 2018).
18F‑FPOIBG
An alternative strategy for the derivation of a fluorine-18 
tracer from MIBG has been to introduce a fluoropropoxyl 
group onto the MIBG core structure, from which 4-[18F]
fluoropropoxy-3-iodobenzylguanidine (18F-FPOIBG) was 
synthesized and compared with MIBG in three different 
NET-expressing cell lines. Uptake studies show that the 
tracer uptake at 2 h was, on average, lower than its lead 
MIBG, counting 18F-FPOIBG with10.2, 38.6, and 13.3%, 
and 125I-MIBG with 57.3%, 82.7%, and 66.3% in SK-N-
SH, UVW-NAT and SK-N-BE(2c) cells, respectively. 
However, the corresponding bromine analogue of FPOIBG 
has demonstrated much higher uptake, with a higher  IC50 
value than either bromide or MIBG (Vaidyanathan et al. 
2015). As a result, although FPOIBG does not provide 
superior in vivo properties than reported tracers, it offers 
a hint at the structure–activity relationships (SARs) of the 
tracers, which may prove useful for further tracer design, 
such as the intolerant iodine and the introduction of 
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3-fluoropropoxyl substitution consistent with N-[3-bromo-
4-(3-fluoro-propoxy)-benzyl]-guanidine (LMI1195).
18F‑LMI1195
Prior to 18F-FPOIBG, 18F-LMI1195 was one of the first 
fluorine-18-labeled PET tracers derived from MIBG’s core 
structure without the direct introduction of fluorine-18 onto 
the benzene ring, avoiding the difficulty of radiofluorina-
tion. Different substitution patterns on the benzene ring/
heterocycles, linkers between aromatic and guanidine moi-
eties with or without β-hydroxyl group, as well as differ-
ent substituted/integral guanidines have been investigated 
and patented by Lantheus Medical Imaging (Purohit et al. 
2008). The chemical structure of LMI1195 was derived 
from MIBG with meta-bromine replacing iodine, with an 
extra para-3-fluoropropoxyl group for convenient radiola-
beling and improved radiochemical yield compared to other 
MIBG derived tracers with direct radiofluorination on the 
electron-rich benzene ring. In this way, LMI1195 could be 
labeled from a brosylate precursor and a single-step fluo-
rine-18 displacement reaction followed by HPLC separation 
(Yu et al. 2011). 18F-LMI1195 has demonstrated compara-
ble in vitro properties to MIBG and more favorable in vivo 
characteristics than MIBG in both rats and rabbits, with clear 
and specific cardiac uptake and better heart-to-liver (H/L) 
ratios than MIBG (Yu et al. 2011). 18F-LMI1195 was used 
in imaging of regional cardiac sympathetic denervation in 
the rabbit model due to its high association with NET (Yu 
et al. 2012). Comparable to either MIBG or HED, LMI1195 
has also showed high and specific accumulation in neuroen-
docrine tumors in the rat model, and more favorably than 
the reference MIBG (Gaertner et al. 2013). Following a 
successful phase 1 clinical trial, in which 18F-LMI1195 has 
demonstrated cardiac imaging potential with comparable 
radiation dose and favorable kinetics (Sinusas et al. 2014), 
it was compared with 11C-HED in a recent publication. The 
preliminary data suggested a highly correlated estimation 
of cardiac sympathetic innervation for both tracers, whereas 
18F-LMI1195 showed significantly elevated heart-to-blood 
(H/B) ratios when compared to 11C-HED (Zelt et al. 2018). 
This leads into further phase 2 clinical trials for the predic-
tion of arrhythmic events and the strategizing of the identifi-
cation of patients who should receive ICD (NCT03493516).
While using rats and rabbits with and without sympa-
thetic neuronal denervation, 18F-LMI1195 exhibited dif-
ferent uptake mechanisms due to species discrepancies: 
LMI1195 cardiac uptake did not change in the rat model 
but was greatly decreased in rabbits following treatment of 
uptake-1 selective blockade using DMI. This stems from 
the existence of extra-neuronal uptake (i.e. uptake-2) in 
the rat heart. A consistent result could be obtained from 
denervated rabbits and nonhuman primates (NHP), for the 
reason that in both animals only uptake 1 is responsible for 
the NET tracer uptake (Yu et al. 2013). Further assessment 
in rats using the non-selective uptake blocker phenoxyben-
zamine (PhB) confirmed the existence of both uptake 1 and 
2 in rat hearts, where the cardiac uptake of 18F-LMI1195 
could only be reduced by PhB, rather than DMI or saline 
control (Higuchi et al. 2013). First-pass tracer extraction 
fraction (EF) and washout were measured in an ex vivo 
study using isolated rabbit hearts, which is chosen due to 
comparable tracer uptake patterns in rabbits and humans. 
Results demonstrated a flow-dependent EF with DMI sen-
sitivity. The irreversible vesicular monoamine transporter 
blocker reserpine pretreatment was unable to change the 
EF. Additionally, an electrical stimulation instead of DMI 
chase (DMI added in washout phase) was able to enhance 
the tracer washout rate, suggesting that the tracer stor-
age and release mode at the nerve terminal was consistent 
with NE (Higuchi et al. 2015). The detailed kinetics of 
LMI11995 at the subcellular level have been confirmed in 
an in vitro study using both PC12 (vesicle-rich) and SK-
N-SH (vesicle-poor) cell lines expressing NET. Both high-
concentration KCl and reserpine were able to induce tracer 
washout due to storage turnover, as such an effect could be 
only observed in vesicle-rich PC12 cells but not in vesicle-
poor SK-H-SH cells. Moreover, such KCl-induced spillo-
ver could be suppressed by the calcium chelator EDTA, 
which is consistent with the fact that the tracer release is 
mediated by a calcium influx resulting from membrane 
depolarization (Chen et al. 2018). Adding to these find-
ings, a high-resolution autoradiography of rabbit heart 
slices following administration of both 18F-LMI1195 and 
201Tl was performed, from which a homogeneous distribu-
tion of the former was observable throughout the LV wall. 
No significant differences were found when compared to 
the slightly discrepant transmural distribution of the latter 
tracer. Should 18F-LMI1195 be used in the clinic, the pre-
sented distinct characteristics in the LV distribution pat-
tern should be considered as preliminary work for imaging 
result evaluation (Werner et al. 2019).
It is crucial that clinicians understand the characteris-
tics of tracer uptake and retention kinetics when deciding 
on their suitable clinical applications. With this aim, 18F-
LMI1195 was compared with 123I-MIBG and 11C-HED 
in rabbit hearts, where all three tracers exhibited DMI 
(pretreatment)-sensitive/neuronal-specific uptake. However, 
cardiac washout of 11C-HED, rather than 18F-LMI1195 and 
123I-MIBG, was influenced by DMI chase (1.5 mg/kg admin-
istered 10 min after tracer injection), indicating a cycle of 
continuous NET uptake, and a 11C-HED release pattern at 
the nerve terminals, in contrast to the stable vesicle stor-
age of the other two tracers (Werner et al. 2015). Consider-
ing the common benzylguanidine core structure of MIBG 
and LMI1195 (vs. the ephedrine of HED), it is possible to 
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combine its chemical structure with its storage kinetics to 
conclude that the polar guanidine moiety retains the tracers 
in storage vesicles, whereas the relatively lipophilic mono-
amine structure of ephedrine can be released from these 
vesicles either passively or together with vesicle turnover.
18F‑4F‑MHPG and 3F‑PHPG
It is noteworthy that the insensitivity of known tracers to 
non-severe regional nerve loss delays possible early stage 
pharmaceutical intervention. Therefore, to overcome the 
rapid neuronal uptake and blood flow dependency of the 
mostly benzylguanidine-based radiotracers, and to provide 
physicians with a NET targeting tracer with more accu-
rate regional denervation estimation, Raffel et al., syn-
thesized over a dozen phenethylguanidine analogues as 
novel core structure of NET radiotracers, and investigated 
their neuronal uptake rate in isolated rat hearts. In this 
study, 11C-N-guanyl-m-octopamine (11C-GMO) showed a 
slow NET transport rate, with improved myocardial kinet-
ics, when compared to HED. In cosntrast, 11C-p-hydroxy-
phenethylguanidine showed a rapid NET transport rate and 
rich accumulation in xenograft tumors in mice (Raffel et al. 
2007). Further compartmental modeling and Patlak analy-
sis of 11C-GMO kinetics in response to different doses of 
DMI in monkey hearts confirmed stable uptake, along with 
the possibility for providing robust and sensitive quantita-
tive measurements of regional NET density (Raffel et al. 
2013a). Meanwhile, several known tracers were evaluated 
in C6-hNET cells to determine their transport constants 
Km and Vmax. Results have confirmed a strong linear corre-
lation between NET-mediated neuronal transport rates and 
their in vitro transport parameters, as given by the ratio 
Vmax/Km. This project provided useful insights into tracer 
structure design and NET transport constants (Raffel et al. 
2013b). Based on this knowledge, 18F-4-fluoro-m-hydroxy-
phenethylguanidine (18F-4F-MHPG) was discovered. It 
features comparable biodistribution to MIBG and HED in 
rats, along with slow cardiac uptake and long-term reten-
tion kinetics in isolated rat hearts. Further NHP PET study 
has proved its feasibility for cardiac imaging by allow-
ing for more accurate quantification of regional cardiac 
sympathetic nerve density (Jang et al. 2013a). A detailed 
biodistribution study revealed low uptake in the lungs and 
liver, in addition to high quality and DMI-sensitive car-
diac imaging. Uptake in adrenal glands has also proved its 
potentiality for oncological application (Jang et al. 2013b). 
With the establishment of the new synthetic approach to 
18F-hydroxyphenethylguanidines, 18F-3-fluoro-p-hydroxy-
phenethylguanidine (18F-3F-PHPG), the structural isomer 
of 18F-4F-MHPG, has been evaluated (Fig. 1a). In monkey 
studies, comparable properties  between18F-3F-PHPG and 
18F-4F-MHPG have been demonstrated, showing higher 
H/B (4.0 vs. 3.0) but slightly lower H/ L ratio (2.2 vs. 
2.5) due to the relatively faster liver clearance of the lat-
ter tracer. Fast clearance of these tracers from the blood 
has been revealed in monkey studies with sulfate as the 
main metabolite of 18F-4F-MHPG, but results are yet 
unclear for 18F-3F-PHPG. The mean time to 50% intact 
radiotracer is 6.7 and 2.3 min (Jung et al. 2017). As a 
result, both 18F-4F-MHPG and 18F-3F-PHPG have been 
evaluated in healthy human subjects, from which the infor-
mation of not only the biodistribution and metabolism, 
but also, more importantly, the potential of quantitative 
estimates of regional cardiac sympathetic nerve density 
could be obtained. These results are consistent with the 
data obtained from the monkey study, with both excellent 
imaging properties and individual kinetic characteristics, 
such as different neuronal accumulation time and liver 
clearance rate (Raffel et al. 2018). A further study involved 
eight patients with HF who underwent cardiac innervation 
PET scans with both tracers while using 13N-ammonia as 
a reference. The results showed that both tracers are able 
to provide reliable quantitative metrics of regional sym-
pathetic nerve density and could be used to strategize HF 
patients for ICD placement (Raffel et al. 2017).
Similar to the case of 18F-MFBG/PFBG, the radiola-
beling of phenethylguanidine tracers started from using 
radioisotope carbon-11 for preliminary evaluation, to 
build up the correlation of chemical structures with NET 
affinity. Due to the aforementioned disadvantages of car-
bon-11 tracers, however, later stage development mainly 
focused on fluorine-18-labeled ones, as exemplified by 
18F-4F-MHPG (Fig. 2). The initial radiofluorination pro-
cedure required four steps because of the requirement of 
the electron-withdrawing group on the benzene ring (Jang 
et al. 2013a), but was soon simplified to four steps but 
one pot reaction including the fluorination from 2-thienyl 
iodonium salt and the following formation of the guani-
dine moiety (Jang et al. 2013b). Although the method has 
been improved, multistep radiolabeling is still time con-
suming with low radiochemical yield that is not suitable 
for clinical application. As a result, this research group 
has kept the iodonium salt precursor but used tetra-Boc 
as protecting groups on the guanidinyl moiety to accom-
plish two-step-one-pot radiolabeling. The procedure was 
applied to both 18F-4F-MHPG and 3F-PHPG, with an aver-
age yield of final product up to 7.0% and 8.0%, respec-
tively (Jung et al. 2017). In exploring new methods that 
offer higher yield, spirocyclic iodonium ylide rather than 
2-thienyl iodonium salt precursor has been used due to the 
even higher electron density offered by the former moiety, 
which could lead to higher yield. Under optimized auto-
mated reaction conditions, the yield increased threefold, 
averaging 7.8%, which the authors claimed being well 
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suited to on-site production for clinical PET studies (Jung 
et al. 2019).
18F‑AF78
Although 18F-4F-MFBG/3F-PFBG  and18F-FIBG are supe-
rior MIBG analogues, their potential clinical applications are 
limited due to the nature of their chemical structures—the 
direct radiofluorination on the electron-rich benzene ring is 
normally not suitable for single-step fluorine-18-labelling. 
Consequently, a long and demanding radiolabeling proce-
dure along with low radiochemical yield has made further 
development challenging. To investigate the relationships 
between the chemical structures of radiotracers and their 
affinity for NET, our research group has recently developed 
a new NET-targeting PET tracer: 18F-1-(3-fluoro-4-(3-
fluoropropoxy)phenethyl)guanidine (18F-AF78). It bears 
a phenethylguanidine core structure of 18F-3F-PHPG for 
potential slow uptake kinetics, but with an easier radiola-
beling procedure and a high yield (27%) as a result of the 
introduction of a 3-fluoropropoxy substitution—a strategy to 
develop 18F-LMI1195 from 123I-MIBG as mentioned above 
(Chen et al. 2019). Cell uptake studies of 18F-AF78 have 
demonstrated an almost identical affinity for NET as NE and 
MIBG. Both ex vivo autoradiography of the rat heart and 
in vivo imaging in rats showed homogeneous and specific 
cardiac uptake throughout the left ventricular wall (Fig. 3). 
High H/B and H/L ratios (12.54 ± 0.53 and 6.14 ± 0.35) have 
also been observed (Chen et al. 2019), and are comparable 
to those of 123I-MIBG (11.91 ± 1.60 and 2.42 ± 0.41) and 
18F-LMI1195 (15.56 ± 3.61 and 6.21 ± 1.68) (Yu et al. 2011). 
Time–activity curves of 18F-AF78 in rats have demonstrated 
stable and long-term cardiac uptake with favorable H/L 
ratios following 10 min of tracer injection, due to the fast 
liver uptake washout (Fig. 3). Currently, the evaluation of 
AF78 in different animal species is still ongoing for further 
in vivo characteristics.
Of note, while developing AF78 from 3F-PHPG, its 
isomer AF51, the corresponding 3-fluoropropoxy deriva-
tive of 4F-MHPG, was also synthesized and evaluated in 
cell uptake assay as well. It demonstrated a great loss of 
NET affinity, which provides an insight into the SARs of 
these NE-derived tracers. To combine the drop of activity 
of derivation from MIBG to FPOIBG as mentioned above, 
a substituent larger than iodine on the meta-position would 
not be tolerable. Consequently, a loss of activity due to the 
introduction of a 3-fluoropropyl group to 4F-MHPG would 
be reasonably explained. The reason for choosing 3-fluoro-
propyl over 2-fluoroethyl is its in vivo stability, as the lat-
ter metabolizes faster through defluorination (Kuchar and 
Mamat 2015). Possible byproduct, such as the formation of 
vinyl from precursors during radiofluorination, could also be 
prevented. Furthermore, the ether that substitutes the phe-
nol might change the kinetics and metabolism of the radi-
otracer in vivo, as it has been proved that one of the major 
metabolites of 4F-MHPG is the sulfate of the phenol (Jang 
et al. 2013b). In addition, ether is more stable against oxida-
tion than phenol, which might be the case of the presumable 
metabolite of 3F-PHPG (Jung et al. 2017). Lastly, cardiac 
uptake may be also related to the chemical properties of 
these radiotracers. For example, LogP, or polar surface area, 
which can be determined by comparing the biodistribution 
data of 4F-MHPG with MIBG and HED (Jang et al. 2013a). 
Of note, when evaluating the biodistribution and kinetics 
Fig. 2  Development of the synthetic scheme for the radiolabeling of 18F-4F-MHPG (Jang et al. 2013a, b; Jung et al. 2017, 2019). This figure was 
created using ChemDraw 16 for Mac
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of 18F-AF78 in different animal species, cardiac uptake 
showed significant differences (unpublished data): it showed 
different modes of cardiac uptake in animals with only the 
uptake-1 mechanism, i.e. the uptake can be fully blocked by 
DMI; and those present both uptake-1 and uptake-2/extra-
neuronal uptake, where the radiotracer uptake can only be 
fully blocked by PhB. These results are in accordance with 
the data obtained from assessing 123I-MIBG, 18F-LMI1195 
and 18F-MHPG/PHPG in different animal models (Rischpler 
et al. 2013; Higuchi et al. 2013; Jang et al. 2013b; Jung 
et al. 2017): these radiotracers would be preferably taken up 
in the heart via uptake-2/extra-neuronal uptake mechanism 
in animals, such as rats and pigs, where both uptake-1 and 
-2 mechanisms present. In contrast, in uptake-1 dominant 
animals, such as rabbits and monkeys, as well as in humans, 
these tracers are primarily taken up in the heart via NET-
mediated uptake-1 mechanisms.
Radiotracers targeting NET in central nervous 
system
As mentioned in the introduction section, malfunction of the 
noradrenergic system in CNS also plays an important role 
in the process of neurodegenerative diseases, depression, 
ADHD, and obesity (Borodovitsyna et al. 2017). Therefore, 
it is conceivable that NET-targeting radiotracers could be 
used to monitor the function of the noradrenergic system 
in the CNS, provide diagnostic information concerning the 
process of these diseases, and instruct therapeutic applica-
tions. However, although all the abovementioned NET-tar-
geting radiotracers can be used for peripheral SNS imaging, 
they are unable to penetrate the blood–brain barrier (BBB), 
most probably due to their polar structures with guanidine 
moieties. As a result, several NET-targeting and BBB-pene-
trating radiotracers have been developed based on clinically 
used and NET-selective antidepressants.
11C‑ME@HAPTHI
Rami-Mark et al. (2013) reported a scaffold using a ben-
zothiadiazole core structure (Fig.  1b) to obtain (S)-1-
(3-hydroxy-4-([11C] methylamino)butyl)-3-phenyl-1,3-
dihydrobenzo[c][1,2,5]thiadiazole 2,2-dioxide (11C-Me@
HAPTHI) based on their previously reported 11C-Me@
APPI. Following successful preparation and radiolabe-
ling, it has displayed good affinity and selectivity for NET 
over the dopamine transporter (DAT) and serotonin trans-
porter (SERT or 5-HTT), which is crucial for the accuracy 
of CNS imaging. It is expected to pass the BBB based on 
the in vitro data. Furthermore, the tracer shows excellent 
metabolic stability in human liver microsomes with > 99% 
intact after 60 min incubation. Autoradiography on human 
brain tissue has revealed NET-specific uptake in NET-
rich regions (Rami-Mark et al. 2015). Notably, in addition 
to CNS uptake, significant cardiac uptake of 11C-Me@


















































































Fig. 3  a Autoradiography of left ventricular short axis slices from 
rats following administration of 18F-AF78 with (right) and without 
(left) NET blockade. b Tissue distribution ratios of 18F-AF78 with 
(hollow column) and without (solid) NET blockade. c Static PET 
images of the uptake of 18F-AF78 in rats with (bottom) and without 
(top) NET blockade 10 min before radiotracer administration (Chen 
et al. 2019). This figure was created using Microsoft PowerPoint ver-
sion 15.38 for Mac then pasted as PDF format into Word file
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chemical structure than abovementioned radiotracers. After 
transient ischemia, reduced 11C-Me@HAPTHI uptake was 
detected in rat hearts from day 1 to 4 weeks, confirmed by an 
increased uptake ratio of ischemic area to the non-ischemic 
area, and increased uptake ratio of non-ischemic area to 
the blood pool. A reduced ratio of cardiac uptake to blood 
radioactivity by the pre-injection of blockers confirms its 
high specificity. Slightly reduced apical 18F-FDG uptake was 
observed in the left ventricle, revealing reduced myocardial 
viability with corresponding sympathetic nerve denervation 
in the heart, as indicated by 11C-Me@HAPTHI uptake in 
the ischemic region (Li et al. 2016). These preliminary data 
have proved the feasibility of cardiac imaging using different 
core structures, opening a door to the development of a new 
series of radiotracers for the diagnosis of cardiac innerva-
tion, and reducing the effect of the subcellular conditions of 
the sympathetic nerve terminals. The fact of being a carbon-
11-labeled tracer might prevent its further application, but 
several ways have been proven possible for the modification 
of this tracer into a fluorine-18-labeled one with improved 
properties.
11C‑MRB
(S,S)-[11C]O-methyl-reboxetine (11C-MRB) is the methyl 
analogue of reboxetine (Fig. 1b), a specific NET inhibitor 
and antidepressant against panic disorders and ADHD. The 
enantiomeric pure tracer was yielded after resolution via 
chiral HPLC (Lin and Ding 2004). Only (S,S)-11C-MRB 
 (IC50 2.5 nM vs. 85 nM of (R,R)-isomer) shows strong 
DMI sensitivity and high specific uptake in the NET-rich 
regions of the brain and heart in baboons (Ding et al. 2003). 
It shows higher specific binding to NET than other NET 
inhibitor-derived ligands, such as nisoxetine or oxaprotiline 
(Ding et al. 2005). In addition, 11C-MRB has a sixfold higher 
affinity for NET than SERT. Although there are conflicting 
results based on a baboon study concerning the sensitiv-
ity and reliability of its utility as a PET radiotracer (Sever-
ance et al. 2007), 11C-MRB studies in rhesus monkeys have 
demonstrated its suitability for the determination of NET 
occupancy, using dose-dependent inhibition by infusion of 
the NET inhibitor atomoxetine (Gallezot et al. 2011). The 
first human study performed involved 24 male subjects. The 
NET density determined by 11C-MRB PET in these subjects 
follows the order of locus coeruleus, thalamus, and caudate 
nucleus, which is in accordance with the results obtained 
from NHP (Logan et al. 2007).
Following the confirmation of its feasibility, 11C-MRB 
has been applied to monitor NET density in the CNS under 
pathological conditions in several different fields, including 
obesity, ADHD, and PD. Noradrenergic dysfunction and 
impaired NE clearance are implicated in obesity. Conse-
quently, the researchers using 11C-MRB PET have come to 
mutual conclusions that the NET availability in the thala-
mus region of obese adults is decreased when compared to 
healthy controls (Li et al. 2014; Bresch et al. 2017). In addi-
tion, by measuring the CNS NET availability, it is possible 
to predict the result of a dietary intervention, and is helpful 
for adjusting treatment options of highly obese adults (Vet-
termann et al. 2018). BAT plays a role in energy balance and 
is also regulated by the SNS. After an initial evaluation of 
11C-MRB in rats, tracer uptake in BAT, with proved specific-
ity under basal, room temperature conditions, was observed 
to be threefold higher than that of 18F-FDG. However, the 
latter one requires cold stimulation for good imaging qual-
ity (Lin et al. 2012). The same result could be replicated in 
humans, showing 11C-MRB uptake in BAT to be equally 
evident under both room temperature and cold conditions, 
though with gender differences (Hwang et al. 2015). When 
11C-MRB PET was further applied to monitor BAT only in 
healthy women, findings were consistent with reports that, 
as mentioned above, NET is decreased in obesity, which sug-
gests that sympathetic innervation of BAT is altered in obe-
sity (Sanchez-Rangel et al. 2019). ADHD is a heterogeneous 
disorder with NET as the key target for treatment. A PET-
MRI study using 11C-MRB has successfully demonstrated 
that, rather than morphological changes, there is a decrease 
in NET availability in fronto–parietal–thalamic–cerebellar 
regions in the brains of ADHD patients (Ulke et al. 2019). 
Cardiac 123I-MIBG scintigraphy has been proposed for 
early detection of PD, but its feasibility as a routine clinical 
practice is limited (Skowronek et al. 2019). The potential 
of evaluating PD patients using 11C-MRB PET has been 
confirmed, and the imaging protocol has been optimized fol-
lowing the investigation of kinetic models. An acquisition 
time of 30 min after 50 or 60 min of tracer injection allows 
for a reliable estimation of NET, which can significantly 
reduce the discomfort of PD patients (Brumberg et al 2019). 
Lastly, in addition to the above applications, 11C-MRB has 
also been used to investigate noradrenergic activation and 
modulation in different regions of the brain in response 
to insulin-induced hypoglycemia (Belfort-DeAguiar et al. 
2018).
18F‑FMeNER‑D2
18F-FMeNER-D2 is a fluorine-18-labeled CNS NET tracer 
that is the di-deuterated analogue of 18F-FMeNER, devel-
oped to improve its in vivo stability by reducing the defluori-
nation (Fig. 1b). A preliminary study in rhesus monkeys 
demonstrated fast and long retention of 18F-FMeNER-D2 
in the thalamus and brainstem (Takano et al. 2009). It is 
prepared by O-fluoromethylation of desfluoromethoxy-
(S,S)-FMeNER with 18F-di-deutero-bromofluoromethane. 
After optimization, fully automated radiolabeling can be 
performed, yielding 1.0–2.5  GBq of formulated tracer 
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within 95 min (Rami-mark et al. 2013). It initially shows 
DMI-sensitive binding to NET in monkeys and in ex vivo 
autoradiography on post-mortem human brains. The tracers 
are localized in the locus coeruleus and thalamus (Schou 
et al. 2004; 2005). An initial in vitro investigation of the 
tracer revealed stability against MAO and catechol-O-me-
thyl transferase (COMT), along with fast metabolism by 
CYP450 enzymes (Rami-Mark et al. 2016). An evaluation 
on the post-mortem AD brain tissue with autoradiography 
showed a significant decrease in NET densities in various 
brain regions (e.g. thalamus), indicating the possible use of 
18F-FMeNER-D2 PET as imaging biomarker in AD (Gulyás 
et al. 2010).
Takano et al. (2008a, b) evaluated the tracer in healthy 
subjects, which showed a good radiation tolerance in the 
entire body, and especially good brain penetration and selec-
tive retention in NET-rich regions. A further study indicated 
that combining the radiotracer with a template method can 
map the distribution of NET in different regions of the brain. 
Functional regions of interest (ROIs) with higher nondis-
placeable binding potential  (BPND) thresholds yielded higher 
 BPND and lower coefficients of variance than did anatomical 
ROIs (Takano et al. 2008c). The regional distribution of the 
tracer is highest in the thalamus and lowest in the caudate, 
which is in accordance with the results demonstrated by pre-
vious PET and post-mortem studies of NET on human brain 
tissue. This opens up the potential of noninvasive estimation 
of NET occupancy by antidepressants (Arakawa et al. 2008).
In recent years, with the solid potential of NET imaging 
in the CNS being proven, 18F-FMeNER-D2 has been used in 
several clinical studies focused on the quantification of NET 
density in ROIs, along with its changes in different related 
diseases. However, quantification of NET in the cerebral 
cortex has been difficult due to the unfavorable kinetics of 
11C-MRB and the defluorination of 18F-FMeNER-D2, along 
with the disadvantages due to the short half-life of carbon-
11-labeld tracers. After systemic evaluation of the tracer 
distribution in ten healthy volunteers, Moriguchi et al. estab-
lished methods for quantifying NET densities in the brain 
through the performance of 90-min dynamic scans, which 
then provided a sufficient amount of data while being unaf-
fected by the defluorination that normally begins to increase 
beyond 120 min (Moriguchi et al. 2017a).
The NET has been suggested to play a crucial role in 
major depressive disorder (MDD), but its availability in this 
disease and its relationship with clinical symptoms are not 
clear. A 19-patient MDD study using 18F-FMeNER-D2 PET 
revealed a positive correlation between  BPND values in the 
thalamus region and altered attention in the patients (Mori-
guchi et al. 2017b). As it binds to NET (i.e. NET targeting), 
18F-FMeNER-D2 can, therefore, not only reveal the distribu-
tion and density of CNS NET but also show NET occupancy 
by antidepressants or antipsychotics. Presently, investigated 
ligands include nortriptyline (Sekine et al. 2010), clomi-
pramine (Takano et al. 2011), quetiapine (Nyberg et al. 
2013), milnacipran (Takano et al. 2013; Nogami et al. 2013), 
nortriptyline (Takano et al. 2014), and duloxetine (Morigu-
chi et al. 2017c), which compete for the transportation via 
NET. In all cases, the estimated administration dose, as well 
as plasma drug concentration, can be obtained to guide the 
drug application. The NET occupancy measurement may 
provide information regarding the spectrum of efficacy of an 
antidepressant. Some reported antidepressant drugs involve 
blockade of both SERT and NET. Using 18F-FMeNER-
D2 PET measurements, it has been proved that venlafax-
ine occupies 8–61% of NET in a dose-dependent manner, 
as seen in a study involving 12 major depressive disorder 
patients who had responded to venlafaxine (Arakawa et al. 
2019a). Thus, 18F-FMeNER-D2 PET can also be used to 
predict the potential of certain drugs as an antidepressants, 
exemplified by the research on tramadol in NHP (Arakawa 
et al. 2019b).
In contrast to the application of 11C-MRB in ADHD, a 
study on 18F-FMeNER-D2 PET by Vanicek et al. (2014) 
found no significant difference in either NET availability or 
distribution in ADHD-relevant regions of the brain. How-
ever, Sigurdardottir et al. (2016) used it to identify the gen-
otype-dependent difference in NET  BPND between healthy 
controls and ADHD patients. It provided further evidence of 
NET imbalance in several brain areas, pointing to epigenetic 
dysfunction in ADHD (Sigurdardottir et al. 2019).
18F‑NS12137
Another CNS fluorine-18-labeled tracer is exo-3-[(6-[18F]
fluoro-2-pyridyl)oxy]-8-azabicyclo[3.2.1]-octane (18F-
NS12137), which is derived from 11C-NS8880 (Vase et al. 
2014), and has shown good selectivity over SERT and DAT 
(Fig. 1b). It has been successfully radiolabeled using both 
the 18F-F2 and 18F-selectfluor methods, with radiochemi-
cal yield 3.9% and 10.2%, respectively (Kirjavainen et al. 
2018). The radiolabeling method was then optimized using 
a copper-mediated pathway and stannane precursor to obtain 
18F-NS12137 with 15.1% yield and up to 300 GBq/µmol 
specific activity (Lahdenpohja et al. 2019a, b). Further opti-
mization of the fluorination using a bromide precursor led to 
18.6% yield and > 500 GBq/µmol specific activity (López-
Picón et al. 2019). Its uptake in NET-rich areas of the rat 
brain was demonstrated with specificity proven by pretreat-
ment of nisoxetine, a known NET antagonist. Defluorination 
and slow increase of bone uptake could be observed after 
time (Kirjavainen et al. 2018). PET imaging in adult and 
immature Sprague–Dawley rats, along with ex vivo stud-
ies using autoradiography, has demonstrated uptake of the 
radiotracer in brain areas rich in NET, especially the locus 
coeruleus, a quite small volume for PET imaging. The tracer 
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shows optimal characteristics (such as fast washout and high 
specificity) that are favorable for NET imaging in the brain 
(López-Picón et al. 2019).
Discussion
NET targeting and NET‑function targeting tracers
The term “NET targeting” has always been used when 
discussing the diagnosis of SNS in the heart, both in other 
reviews and in the present one. However, it is worth men-
tioning that all the cardiac radiotracers described above 
are actually “NET function targeting”, because they will 
be taken up by NET and transported into the neurons, 
particularly granular vesicles, with the exception of 11C-
HED as discussed above (Werner et al. 2015). Therefore, 
the PET signal reflects the transportation/density of NET, 
which relies on the structural integrity of the sympathetic 
neurons. In addition, there are also NET structure-tar-
geting radiotracers, mostly derived from antidepressants 
and mainly used in the imaging of NET density in the 
CNS. The rationale behind this is the lipophilicity of these 
compounds. On the one hand, this allows them to easily 
pass the BBB, on the other hand, it may lead to high liver 
uptake that is not ideal for cardiac imaging due to the scat-
tering effect. As a result, there is almost a clear-cut bound-
ary between cardiac NET tracers and CNS NET tracers: 
the former ones are majority NET function-targeting trac-
ers with polar benzylguanidine or phenethylguanidine 
structures, whereas the latter ones are mostly derived from 
known NET-selective antidepressants with BBB penetra-
tion properties. Researchers have attempted to modify the 
chemical structure of MIBG by introducing 1,4-dihyd-
roquinoline as chemical delivery system to improve its 
uptake in the brain, but the result requires further optimi-
zation (Gourand et al. 2019). The structural–functional 
difference is due to the different properties between the 
heart and the brain. Assessment of sympathetic innerva-
tion depends on both the blood flow—through which the 
tracer reaches the target tissue—and the NET uptake kinet-
ics. Subsequently, most known radiotracers, such as MIBG 
and LMI1195, are quickly transported into the neurons 
and therefore cannot be used to quantify NET density pre-
cisely. The design rationale of 3F-MHPG and 4F-PHPG by 
researchers from University of Michigan counteracted this 
issue by introducing tracers with slow-uptake mechanisms, 
which has been proven in ex vivo rat heart studies, and in 
NHP (Raffel et al. 2007). Clinical trials of these tracers are 
still ongoing, and further proofs of the concept are needed.
NET tracer specificity and selectivity
In this review, we have provided an overview of the cur-
rently reported NET radiotracers derived from its natural 
substrate, NE, or NET-selective antidepressants. This has 
included not only their preclinical evaluation and clinical 
application, but also their potential use in the fields other 
than heart and neuroendocrine tumors. Several carbon-11 
and fluorine-18-labeled tracers derived from antidepres-
sant drugs with chemical structures different from cardiac 
ones have been used in the investigation of CNS imag-
ing, in the context of ADHD and PD, for example. The 
advantages of using carbon-11 radioisotope are: the easy 
access to their corresponding precursors, along with their 
unchanged chemical structures and biological properties 
in vivo, particularly when the CNS is involved, as the 
development of new structures by chemists requires much 
longer time. In addition, the new generation of fluorine-
18-labeled PET tracers, such as 18F-LMI1195 and 18F-4F-
MHPG/3F-PHPG, has already reached clinical trials, and 
demonstrated excellent imaging quality and spectacular 
kinetic advantages of quantifying regional innervation. 
Furthermore, the distinctive slow neuronal uptake and 
long-term neuronal retention in the heart represented by 
the phenethylguanidine series of NET-function targeting 
tracers has provided clinicians with more possibilities for 
quantitatively measuring regional denervation conditions. 
Thus, from the classical SPECT tracer 123I-MIBG, with its 
benzylguanidine core structure, to the latest easily labeled 
PET tracer, 18F-AF78, more details regarding the struc-
ture–activity relationships of these NET-function targeting 
radiotracers have been revealed, which is helpful for the 
design of new generation PET tracers.
However, it should be mentioned that the currently 
available radiolabeled tracers or therapeutic agents are not 
selective to NET transport function. In the human or animal 
body, several extra-neuronal uptake mechanisms, or non-
adrenergic uptake, such as DAT and SERT uptake, also exist 
and are responsible for the extraction and excretion of these 
radiotracers into or through different organs, which may lead 
to unfavorable uptake and corresponding side effects. Due 
to the fact that either the guanidine moiety of the MIBG-
derived NET-function targeting tracers or antidepressant-
derived NET-targeting CNS tracers would be in cation form 
under physiological conditions, organic cation transporters 
(OCTs) are considered to contribute most to these extra-
neuronal uptake mechanisms (Fig. 4). Among the subtypes 
of the OCT family, OCT1 and OCT2 are critical for the 
elimination of a wide array of drugs and environmental tox-
ins and are restricted mainly to excretory organs, dominantly 
in the liver and kidney, respectively (Solbach et al. 2011), 
which may be the molecular basis of the liver or kidney 
uptake of radiotracers. OCT3 transports a wide range of 
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monoamine neurotransmitters, hormones, and steroids and 
shows a much broader tissue distribution, including skeletal 
muscle, heart (Solbach et al. 2011), brain (Wu et al. 1998; 
Gasser and Lowry 2018), and placenta (Chen et al. 2010). 
Although OCT3 has a major expression in the brain, it is 
unlikely that the currently reviewed tracers with guanidine 
moieties will be able to penetrate the BBB due to their very 
polar guanidine structures. Such radiotracers targeting NET, 
yet mediated by OCT3 uptake in the CNS, would be pru-
dently considered.
Until now, although several radiotracers targeting NET 
transport-function have been reported, no NET-selective 
compound has been reported and no such agent has been 
approved for clinical application. All the research focus is 
on either NET or OCTs alone, but without correlating the 
OCT-dependent side effects to improve the NET-selectivity 
for higher accuracy diagnosis and higher efficiency cancer 
therapy. As the only NET-function targeting tracer cur-
rently applied clinically, 123/131I-MIBG is not exclusively 
selective towards NET but can be also taken up by OCTs in 
both animal models and humans. Consequently, its uptake 
might not accurately reflect the SNS function of the heart 
or properly affect cancer therapy, which urges the develop-
ment of radiotracers with higher NET selectivity over OCTs, 
for better imaging accuracy and therapeutic specificity. Ito 
et al. (2012) have already proven MIBG uptake via hOCT1 
and hOCT2 in HEK295 cells. First, less NET-selective 
radiotracers with intensive liver uptake, presumably via 
OCT1, decrease the H/L contrast and make it difficult to 
interpret the condition of the heart in the LV inferior wall. 
Photon scattering from high liver radioactivity accumulation 
remains a challenge for the diagnosis of heart diseases (Kim 
et al. 2010). Second, researches, such as 123I-MIBG imag-
ing involving therapy-resistant hypertension patients before 
and after catheter-based renal sympathetic denervation or 
kidney autotransplantation (Dobrowolski et al. 2015, 2018), 
have proven the uptake of MIBG into kidney irrelevant to 
sympathetic nerve activity in the kidney, presumably due 
to its non-specific uptake via OCT2 or other transporters. 
Thus, a NET-selective tracer would open a new door for the 
diagnosis of renal sympathetic innervation. Furthermore, 
decreased OCT activity of NET-targeting radiotracers may 
reduce the fast excretion through kidneys and the rapid uri-
nary elimination, which has always resulted in the bladder 
being the actual critical organ for imaging or therapy. There-
fore, a higher NET selectivity might reduce the speed of 
excretion, which would consequently reduce the overall dose 
administration and the corresponding unnecessary off-target 
radiation exposure. Third, in addition to the specific tumor 
uptake required for diagnostic and therapeutic applications, 
non-tumorous tissues also incorporate MIBG through OCTs 
(Bayer et al. 2009, 2016), which will reduce the effective 
radiation dosage for the target organ while causing an unnec-
essarily high dose utilization of radioactivity and delayed 
toxicity in these related organs. It has been reported that with 






































Fig. 4  Illustration of simplified NET-targeting radiotracer biodistribution. This figure was created using Microsoft PowerPoint version 15.38 for 
Mac then pasted as PDF format into Word file
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MIBG in patients was reduced due to the blocking of OCTs 
(Bayer et al. 2016). Therefore, it is conceivable that with 
NET-selective radiotracers and derivatives, such additional 
drug intervention can be prevented and the radiation dose 
required could be further decreased, especially when juve-
nile or elderly patients are involved (Agrawal et al. 2018). It 
is crucial to summarize the SARs of the radiotracers selec-
tively targeting NET over OCTs using different cellular- and 
animal-based models, which is helpful for elucidating the 
role of OCTs in drug design and kinetics optimization.
A NET tracer might also be taken up by other monoamine 
transporters, such as DAT and SERT. Both play very minor 
roles in the heart as far as it is reported. However, in the 
CNS, it is crucial to investigate the selectivity of radiotracers 
targeting CNS NET, both in cell-based assays and in ani-
mal studies. Therefore, a blocking study, i.e. a pretreatment 
with DMI that significantly reduces the uptake of potential 
NET tracers, is always performed in all in vitro and in vivo 
studies. DMI has been proven as a NET selective blocker 
with minor effects on SERT (Biaggioni and Robertson 2012; 
Owens et al. 1997; Tatsumi and Groshan 1997). Further 
study in a rabbit model confirmed that the dosage required 
to inhibit MIBG uptake is much higher with escitalopram 
than with DMI. These results proved that MIBG uptake is 
selective to NET over SERT (Werner et al. 2018). In an 
early study investigating MIBG uptake by sympathetic neu-
rons, the human NET, bovine DAT, and the rat SERT were 
cloned and expressed in various cell lines. The results also 
demonstrated nanomolar-range inhibition of MIBG uptake 
by DMI, with no significant uptake by bovine DAT or rat 
SERT (Glowniak et al. 1993). As a result, it is reasonable to 
believe that these reported NET tracers are relatively selec-
tive to NET over DAT and SERT (Table 1). As discussed in 
the last section, most of the cardiac NET tracers are NET 
function targeting ones, which are stored in granular vesi-
cles. Therefore, most of them show a VMAT2 affinity that 
allows them to be transported into the vesicles. It is difficult 
to summarize the pharmacological data of all reported NET 
tracers, since the in vitro and in vivo studies are normally 
performed in a large variety of cell lines, tissues, and animal 
species. Many targets were not considered while develop-
ing these tracers. Therefore, the results cannot be clearly 
presented using accurate numbers, such as an  IC50 values. 
For the reader’s convenience, we attempted to organize the 
related data of selected NET tracers into a table containing 
the transporters discussed in the current review (Table 1). 
Among them, MIBG has received most of the attentions 
and has been investigated at a variety of targets relatively 
thoroughly over 30 years of clinical application.
Limitations of the current strategy 
for the development of cardiac NET tracers
Currently, there are three categories of cardiac NET trac-
ers: (1) those derived directly from NE; (2) those derived 
from MIBG with a benzylguanidine core structure; (3) 
those with a phenethylguanidine core structure. The trac-
ers from category 1, exemplified by 11C-ephedrine and 
11C-phenylephrine, are not metabolically stable against 
MAO. On the one hand, the guanidine moiety in catego-
ries 2 and 3 improves not only the stability of these tracers 
against MAO, but also increases the hydrophilicity that is 
helpful for reducing liver uptake where nonpolar structures 
are preferred. On the other hand, the guanidine structure, 
as suggested by the investigation of metformin, is the sub-
strate for OCT1 and OC2. Thus, unfavorable uptake in the 
off-target tissues increases, as discussed in the last section. 
Furthermore, NET structure-targeting tracers derived from 
antidepressants are not preferable in the cardiac imaging due 
to their high lipophilicity and consequent high liver uptake. 
11C-Me@HAPTHI is one of the few nonpolar tracers that 
shows both CNS and cardiac NET uptake ability. However, 
such research is still in its preliminary stages and, to form 
a more objective judgment, it is necessary to address the 
changing of the radionuclide from carbon-11 to fluorine-18, 
as well as properties such as organ selectivity, in vivo stabil-
ity and kinetics. In addition to the abovementioned tracers, 
11C-HED, with its metaraminol structure, is a special type 
of NET tracers. It has an amine instead of guanidine-based 
structure yet is still MAO stable due to its N- and α-methyl 
substituents. It is suggested to be taken up via uptake-1/NET 
selectively, possibly with low affinity at OCT3. Neverthe-
less, in addition to the disadvantages stemming from carbon-
11-labeling, its special storage mode—constant leaking and 
reuptake—makes the calculation of parameters reflecting 
integrity of NE turnover difficult. In summary, there are still 
areas for improvement in designing an optimal NET tracer 
with NET specificity and ideal in vivo kinetics. A thorough 
investigation on the ligands and radiotracers targeting NET 
will provide useful information as well as a paradigm for 
obtaining highly selective NET-targeting theranostic ligands 
with selectivity over other transporters, especially OCTs.
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